Corcept Therapeutics | CORT - Cash And Equivalent


Corcept Therapeutics reported $120.49M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 819.69M 27.33M Dec/2025
Alaunos Therapeutics USD 1.94M 941K Sep/2025
ANI Pharmaceuticals USD 285.58M 22.98M Dec/2025
Ardelyx USD 42.72M 47.32M Sep/2025
Assertio Holdings USD 38.5M 8.59M Sep/2025
Aurora Cannabis CAD 95.69M 44.47M Sep/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Canopy Growth CAD 298.06M 171.86M Sep/2025
Corcept Therapeutics USD 120.49M 4.64M Dec/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
J&J USD 19.71B 1.48B Dec/2025
Knight Therapeutics CAD 81.88M 4.06M Sep/2025
Lexicon Pharmaceuticals USD 21.36M 41.52M Jun/2025
Merck USD 18.17B 10.16B Sep/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Omeros USD 1.9M 2.36M Jun/2025
Pacira USD 158.54M 10.96M Dec/2025
Pfizer USD 1.34B 295M Sep/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
TG Therapeutics USD 199.51M 21.2M Dec/2025